Nobiletin as an inducer of programmed cell death in cancer: a review

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer therapy faces significant challenges due to tumor resistance mechanisms that inhibit cell death.
• Tumor cells often exhibit reduced tumor suppressor gene activity and impaired anti-tumor immunity, promoting resistance to apoptosis, ferroptosis, and other cell death pathways.
• Upregulation of mediators like Akt, NF-κB, STAT3, and Bcl-2 contributes to cancer cell survival and therapeutic resistance.

Purpose of the Study:

• To review the cellular and molecular mechanisms by which Nobiletin (NOB) induces programmed cell death in cancer.
• To explore NOB's potential as an adjuvant therapy by modulating various cancer cell death pathways.

Main Methods:

• This review synthesizes existing research on Nobiletin's anti-cancer properties and mechanisms of action.
• Focuses on NOB's role in inducing endogenous reactive oxygen species (ROS) generation and subsequent damage to macromolecules.
• Examines NOB's modulation of key signaling pathways, including p53 activation, pro-apoptotic mediator induction, and anti-apoptotic mediator inhibition.

Main Results:

• Nobiletin (NOB) demonstrates potent anti-cancer effects by inducing cancer cell death through multiple programmed cell death mechanisms.
• NOB triggers the generation of endogenous reactive oxygen species (ROS), leading to critical macromolecular damage and cell demise.
• NOB modulates apoptosis by upregulating p53 and pro-apoptotic factors while downregulating anti-apoptotic factors.

Conclusions:

• Nobiletin (NOB) represents a promising therapeutic agent for overcoming cancer resistance by effectively inducing various forms of programmed cell death.
• NOB's ability to modulate ROS production and key apoptotic pathways highlights its potential as a novel anti-cancer strategy.
• Further research into NOB's mechanisms could lead to improved cancer treatment protocols and enhanced therapeutic outcomes.